NASDAQ:KTTA
Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp. reported net income of −$20.4M in fiscal 2025. The diluted share count rose 541.5%.Summary generated from Pasithea Therapeutics Corp.'s SEC filings. Latest annual report filed Mar 30, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−58.4%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+541.5%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | n/a | n/a | n/a |
| Operating income | −5 | −13 | −16 | −14 | −21 |
| Net income | −2 | −14 | −16 | −14 | −20 |
| Free cash flow | −3 | −15 | −13 | n/a | n/a |
Recent filings
- 8-KOther events
Sep 16, 2026 - 8-KResults of a shareholder vote
Sep 9, 2026 - 8-KNotice of delisting or listing-rule failure
Aug 21, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - DEF 14AProxy statement
Aug 7, 2026 - 4Insider transaction report
Jun 22, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 15, 2026 - 4Insider transaction report
May 5, 2026